Literature DB >> 3569027

Tobramycin elimination rate change from first to later doses in older cystic fibrosis patients.

G W Horner, D A Stempel.   

Abstract

Adults with cystic fibrosis frequently require larger than usual tobramycin dosages in order to achieve desired serum concentrations. The application of dosing methods utilizing first-dose pharmacokinetics has been advocated as a means for rapidly attaining therapeutic serum concentrations. Review of ten cystic fibrosis patients between ages 13 and 33 years admitted for exacerbation of pulmonary disease caused primarily by Pseudomonas aeruginosa (Staphylococcus aureus in two patients) was conducted. Elimination rate constant (ke, h-1) was calculated from two concentration-time pairs obtained following the first dose. Two concentration-time pairs were again measured between cumulative doses (n) 7 to 19, and ke was calculated. First dose ke varied significantly from nth dose ke (p = 0.018). First-dose pharmacokinetic analysis may not be a reliable predictor of maintenance tobramycin dosage requirements due to apparent changes in ke over time.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3569027     DOI: 10.1177/106002808702100309

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  2 in total

1.  Population pharmacokinetics of mycophenolic acid in lung transplant recipients with and without cystic fibrosis.

Authors:  Xiao-Xing Wang; Meihua R Feng; Hugh Nguyen; David E Smith; Diane M Cibrik; Jeong M Park
Journal:  Eur J Clin Pharmacol       Date:  2015-05-07       Impact factor: 2.953

Review 2.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.